Transcript Philanthropy - Robert Mallett Presentation

The Infectious Diseases Institute
Kampala, Uganda
InfoPoverty World Conference
United Nations
Robert L. Mallett
Senior Vice President
Corporate Affairs
Pfizer Inc
What We Do
Compound Success
Rates by Stage
Years
Discovery
(2–10 Years)
0
2
4
Preclinical Testing
Laboratory and
Animal Testing
5,000–10,000
Screened
6
Phase I
20–80 Healthy Volunteers
Used to Determine Safety
and Dosage
Phase III
1,000–5,000 Patient
Volunteers Used to
Monitor Adverse Reactions
to Long-term Use
8
10
12
14
Additional
Post-marketing Testing
Phase II
100–300 Patient Volunteers
Used to Look for Efficacy and
Side Effects
FDA Review Approval
250
Enter Preclinical
Testing
5
Enter
Clinical
Testing
16
1
Approved by
the FDA
Source: PhRMA, based on data from Center for the Study of Drug Development, Tufts University, 1995
2
What We Believe
Guiding Principles
• Effective Social Investment
• We Focus on Where We Add the Greatest Value
– Long-Term Commitment to Health Problems
– Focus on Achievable,
Measurable Health Outcomes
– Leverage the Full Resources
of the Company
– Fostering Innovative Approaches
to Public Health Challenges
• We Have More to Offer Than Money
– Medicines, Organizational Influence,
Leadership, and Our People
• We Cannot Do It Alone
– We Work in Partnership
3
How We Help
Global Health: Systemic Improvements in Building Capacity
Access to Medicines
• Infrastructure Development
• Health Provider Training
• Company Expertise
• Patient Education
• Pfizer People
4
Health Care in Uganda:
Challenges and Opportunities
Challenges
Opportunities
• Absence of Primary Health
Care Infrastructure
• Responsive, Engaging
Government
• Lack of Trained Health
Care Professionals
• Existing Medical School
with Significant HIV/AIDS
Expertise
• Transient, Mobile Patient
Populations
• Lack of Equipment and
Medical Facilities
• Stable Environment
• Resources and
International Donors
• Vertical Programs
5
Infectious Diseases Institute,
Kampala, Uganda
Goal: To Build and Sustain Regional Clinic, Laboratory
and Medical Training Center for the Diagnosis, Treatment
and Prevention of HIV/AIDS
6
Model Partnership
• Makerere University in Kampala
– One of the Leading Medical Schools on the Continent
• San Francisco AIDS Foundation/Pangaea
– Program Administration and Project Manager for Construction
• Infectious Diseases Society of America (IDSA)
– Developed Intensive Month-Long HIV/AIDS Training
Curriculum and Provides Trainers
• The AIDS Support Organization (TASO)
– Largest Indigenous Organization in Africa Providing Patient
Counseling and Support
• Pfizer
– Financial Support and
Technical Assistance (e.g. Pfizer
Engineers and IT Support;
Medicines; Pfizer Global Health Fellows)
7
Matching Needs to Resources
IDI Technology Needs
Donors
• Infrastructure/Wiring
($1.8M in IT support )
• Integration of Clinical
Laboratory System
• Pfizer
• Identification and
Implementation of an
Electronic Record Keeping
System
• Cisco
• Installation of a Research
Database to Administer Data
Collection for Clinical Trials
• Hewlett Packard
• Creation of a Clinical
Training Program for New
Physicians
• Skyscape
• Microsoft
• SAS
• Oracle
• Elsevier Science
• PALM Inc
8
Impact of Infectious Diseases
Institute
Training
• 200 Physicians Trained Each Year
Treatment
• 3,000+ Patients Receive Regular Care
Operational Research
• New Studies on Adherence
Prevention and Outreach
• Counseling for Patients
• AIDS Center Provides Information for
Physicians
9
Critical But Unforeseen Benefits
• Workplace Safety Program
– Transferring World Class Health & Safety Standards
• Makerere School of Architecture
– Students Benefiting From Project Engineering and
Architecture
• Local Procurement of Resources
– Support Kampala Economy
• Creating Entrepreneurial Opportunities
– Local Contracting Company Won Bid to
Construct New British High Commission
• Sharing Best Practices
– Pfizer Promoting Lessons Learned
10